Sector News

Merck buys OncoEthix for $375m

December 19, 2014
Life sciences
Just days after announcing its mega-deal with Cubist Merck & Co is on the acquisition trial again with its sights set on private Swiss cancer biotech OncoEthix.
 
The drug giant, which is known as MSD outside the US and Canada, said today it is acquiring the firm to expand its oncology profile, taking OncoEthix’ novel oral BET (bromodomain) inhibitors – including lead candidate OTX015 – into its fold.
 
OTX015, which is currently being tested in Phase Ib studies for the treatment of haematological malignancies and advanced solid tumours, “has demonstrated early promising activity” and “strategically complements” Merck’s immuno-oncology development program, the firm said.
 
From the other side, OncoEthix said it is confident that the deal “best positions OTX015 to be developed to its full potential in areas of high unmet medical need”.
 
Under the deal, Merck will hand out an upfront payment of $110 million to OncoEthix, as well as additional milestone payments of up to $265 million if certain clinical and regulatory events are achieved.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach